Recombinant human papillomavirus type l1 protein

Gardasil

40 MCG / 0.5 ML + 40 MCG / 0.5 ML + 20 MCG / 0.5 ML + 20 MCG / 0.5 ML SuspensionCanadaCancelledAuthorised 16 Aug 2006

Open in the registerAsk Osler about it

This page is kept for reference and is not offered to search engines.

In other countries

The same active substances on other registers, the same brand first.

Gardasil 9, suspensie voor injectieNetherlands · Suspensie voor injectie · Merck Sharp & Dohme B.V.Same brand
Gardasil 9 suspensie voor injectie in een multidoseringscontainerNetherlands · Suspensie voor injectie · Merck Sharp & Dohme B.V.Same brand
Gardasil, suspensie voor injectieNetherlands · Suspensie voor injectie · Merck Sharp & Dohme B.V.Same brand

Documents

The official texts, at the regulator.

Register entry

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Recombinant human papillomavirus type l1 protein

Gardasil

40 MCG / 0.5 ML + 40 MCG / 0.5 ML + 20 MCG / 0.5 ML + 20 MCG / 0.5 ML SuspensionCanadaCancelledAuthorised 16 Aug 2006

Open in the registerAsk Osler about it

This page is kept for reference and is not offered to search engines.

In other countries

The same active substances on other registers, the same brand first.

Documents

The official texts, at the regulator.

Register entry

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Health Canada

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Health Canada, Canada

Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.

Licence: Open Government Licence Canada · Added 13 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Recombinant human papillomavirus type l1 protein
Strength: 40 MCG / 0.5 ML + 40 MCG / 0.5 ML + 20 MCG / 0.5 ML + 20 MCG / 0.5 ML
Dosage form: Suspension
Route: Intramuscular
Register: Canada (Health Canada)
Status: Cancelled
Status in the register: Cancelled Post Market
Authorised: 16 Aug 2006
Registration: DIN 02283190
Marketing authorisation holder: Merck Canada INC
ATC code: J07BM01
Group: Anti-infectives for systemic use
Supply: SCHEDULE D

Canada